#United States #New York #Prostate Cancer #Nucs AI #TrackPSMA

Nucs AI's Breakthrough Tool: TrackPSMA

Nucs AI, a recognized leader in AI-driven radiology solutions, has officially launched TrackPSMA, a pivotal tool designed to enhance the evaluation process of treatment responses in prostate cancer. This innovation addresses two significant hurdles: identifying patients who stand to gain from radioligand therapy and establishing standardized methods for assessing treatment efficacy.

Understanding the Need for TrackPSMA

Statistically, studies indicate that a staggering 54% of prostate cancer patients undergoing radioligand therapy may not benefit from the treatment. This alarming figure underscores the necessity of early identification of non-responders to pivot away from ineffective therapies toward more promising alternatives.

Moreover, for patients showing positive results, TrackPSMA utilizes AI technology to provide physicians with precise, quantitative insights regarding treatment effectiveness. This capability enables tailored approaches that maximize long-term benefits while minimizing patient exposure to unnecessary treatments.

How TrackPSMA Operates

TrackPSMA operates by automatically analyzing PSMA-PET/CT scans of the same patient over time, thereby facilitating the monitoring of treatment responses. Physicians can identify changes in disease progression swiftly and make informed decisions about ongoing care.

Key features of TrackPSMA include:

• - Quantitative Assessments: The tool delivers comparative evaluations of disease from both screening and follow-up scans. This innovation aims to replace traditional unstructured and inconsistent methods with a standardized process.
• - Lesion Tracking: It allows for detailed tracking of individual lesions, offering a true longitudinal analysis of a patient’s condition over time.

This process drastically improves efficiency, providing results in seconds instead of hours or days, and offers physicians the confidence to make timely, data-driven decisions.

Expert Insights on TrackPSMA

Farid Yagubbayli, CTO of Nucs AI, remarked, "Being able to monitor disease progression at the level of individual lesions marks a significant advancement in how we manage cancer. For the first time, therapy responses can be measured with objectivity and reproducibility."

Nijat Ahmadov, CEO of Nucs AI, added, "TrackPSMA is a leap forward in integrating AI into RLT planning. By offering automated, standardized assessments from scans, we’re enhancing drug manufacturers’ understanding of effective treatments while identifying areas that may still require different strategies."

Benefits of TrackPSMA

With the introduction of TrackPSMA, a paradigm shift occurs in how physicians assess treatment effectiveness for radiopharmaceuticals. By harnessing the power of AI, Nucs AI has achieved remarkable outcomes:

• - Reduction in Manual Analysis: Physicians can devote more time to patient care rather than tedious manual evaluations.
• - Improved Patient Stratification: Effective patient categorizations can lead to better health outcomes and more targeted therapies.
• - Lower Healthcare Costs: Efficient workflows contribute to reduced operational costs within healthcare systems, benefiting taxpayers and patients alike.

The launch of TrackPSMA is part of Nucs AI's broader initiative to redefine the landscape of AI in medical imaging. Collaborations with esteemed institutions like Johns Hopkins signify a robust commitment to advancing AI-powered radiology solutions on a global scale.

Conclusion

As healthcare evolves, the importance of precise and effective treatment evaluation becomes undeniable. TrackPSMA stands at the forefront of this revolution, not only enhancing clinician capabilities but ultimately benefiting patients suffering from prostate cancer. With this launch, Nucs AI continues to set a new standard in the field of medical imaging and diagnostics, ensuring future advancements align closely with patient needs and treatment efficacy.